Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 287

1.

Characterization of a beta-catenin nuclear localization defect in MCF-7 breast cancer cells.

Jamieson C, Mills KM, Lui C, Semaan C, Molloy MP, Sharma M, Forwood JK, Henderson BR.

Exp Cell Res. 2016 Feb 1. pii: S0014-4827(16)30021-0. doi: 10.1016/j.yexcr.2016.01.020. [Epub ahead of print]

PMID:
26844628
2.

Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature.

Castagna D, Budd DC, Macdonald SJ, Jamieson C, Watson AJ.

J Med Chem. 2016 Jan 28. [Epub ahead of print]

PMID:
26745766
3.

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.

Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, O'Connell A, McLachlan KR, Zheng X, Radich J, Baccarani M, Kantarjian HM, Levin WJ, Cortes JE, Jamieson C.

Lancet Haematol. 2015 Aug;2(8):e339-46. doi: 10.1016/S2352-3026(15)00096-4. Epub 2015 Jul 26.

PMID:
26688487
4.

Emery-Dreifuss muscular dystrophy mutations impair TRC40-mediated targeting of emerin to the inner nuclear membrane.

Pfaff J, Rivera Monroy J, Jamieson C, Rajanala K, Vilardi F, Schwappach B, Kehlenbach RH.

J Cell Sci. 2016 Feb 1;129(3):502-16. doi: 10.1242/jcs.179333. Epub 2015 Dec 16.

PMID:
26675233
5.

Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal.

Holm F, Hellqvist E, Mason CN, Ali SA, Delos-Santos N, Barrett CL, Chun HJ, Minden MD, Moore RA, Marra MA, Runza V, Frazer KA, Sadarangani A, Jamieson CH.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15444-9. doi: 10.1073/pnas.1506943112. Epub 2015 Nov 30.

6.

Rac1 augments Wnt signaling by stimulating β-catenin-lymphoid enhancer factor-1 complex assembly independent of β-catenin nuclear import.

Jamieson C, Lui C, Brocardo MG, Martino-Echarri E, Henderson BR.

J Cell Sci. 2015 Nov 1;128(21):3933-46. doi: 10.1242/jcs.167742. Epub 2015 Sep 24.

7.

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis.

Jamieson C, Hasserjian R, Gotlib J, Cortes J, Stone R, Talpaz M, Thiele J, Rodig S, Pozdnyakova O.

J Transl Med. 2015 Sep 10;13:294. doi: 10.1186/s12967-015-0644-4.

8.

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.

Choi MY, Widhopf GF 2nd, Wu CC, Cui B, Lao F, Sadarangani A, Cavagnaro J, Prussak C, Carson DA, Jamieson C, Kipps TJ.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S167-9. doi: 10.1016/j.clml.2015.02.010. Review.

9.

RNA rewriting, recoding, and rewiring in human disease.

Zipeto MA, Jiang Q, Melese E, Jamieson CH.

Trends Mol Med. 2015 Sep;21(9):549-59. doi: 10.1016/j.molmed.2015.07.001. Epub 2015 Aug 7. Review.

PMID:
26259769
10.

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.

Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H, Talpaz M.

Blood Cancer J. 2015 Aug 7;5:e335. doi: 10.1038/bcj.2015.63.

11.

The Discovery of in Vivo Active Mitochondrial Branched-Chain Aminotransferase (BCATm) Inhibitors by Hybridizing Fragment and HTS Hits.

Bertrand SM, Ancellin N, Beaufils B, Bingham RP, Borthwick JA, Boullay AB, Boursier E, Carter PS, Chung CW, Churcher I, Dodic N, Fouchet MH, Fournier C, Francis PL, Gummer LA, Herry K, Hobbs A, Hobbs CI, Homes P, Jamieson C, Nicodeme E, Pickett SD, Reid IH, Simpson GL, Sloan LA, Smith SE, Somers DO, Spitzfaden C, Suckling CJ, Valko K, Washio Y, Young RJ.

J Med Chem. 2015 Sep 24;58(18):7140-63. doi: 10.1021/acs.jmedchem.5b00313. Epub 2015 Jul 2.

PMID:
26090771
12.

Catalytic amidation of unactivated ester derivatives mediated by trifluoroethanol.

Caldwell N, Jamieson C, Simpson I, Watson AJ.

Chem Commun (Camb). 2015 Jun 11;51(46):9495-8. doi: 10.1039/c5cc02895g.

PMID:
25966325
13.

Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.

Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, Karin M.

Nature. 2015 May 7;521(7550):94-8. doi: 10.1038/nature14395. Epub 2015 Apr 29.

14.

Rational Design of a Novel AMPA Receptor Modulator through a Hybridization Approach.

Caldwell N, Harms JE, Partin KM, Jamieson C.

ACS Med Chem Lett. 2015 Feb 11;6(4):392-6. doi: 10.1021/ml5004553. eCollection 2015 Apr 9.

PMID:
25893038
15.

GLI2 inhibition abrogates human leukemia stem cell dormancy.

Sadarangani A, Pineda G, Lennon KM, Chun HJ, Shih A, Schairer AE, Court AC, Goff DJ, Prashad SL, Geron I, Wall R, McPherson JD, Moore RA, Pu M, Bao L, Jackson-Fisher A, Munchhof M, VanArsdale T, Reya T, Morris SR, Minden MD, Messer K, Mikkola HK, Marra MA, Hudson TJ, Jamieson CH.

J Transl Med. 2015 Mar 21;13:98. doi: 10.1186/s12967-015-0453-9.

16.

An RNA editing fingerprint of cancer stem cell reprogramming.

Crews LA, Jiang Q, Zipeto MA, Lazzari E, Court AC, Ali S, Barrett CL, Frazer KA, Jamieson CH.

J Transl Med. 2015 Feb 12;13:52. doi: 10.1186/s12967-014-0370-3.

17.

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA.

J Natl Compr Canc Netw. 2015 Apr;13(4):424-34.

PMID:
25870379
18.

Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development.

Smith EN, Ghia EM, DeBoever CM, Rassenti LZ, Jepsen K, Yoon KA, Matsui H, Rozenzhak S, Alakus H, Shepard PJ, Dai Y, Khosroheidari M, Bina M, Gunderson KL, Messer K, Muthuswamy L, Hudson TJ, Harismendy O, Barrett CL, Jamieson CH, Carson DA, Kipps TJ, Frazer KA.

Blood Cancer J. 2015 Apr 10;5:e303. doi: 10.1038/bcj.2015.14.

19.

Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers.

DeBoever C, Ghia EM, Shepard PJ, Rassenti L, Barrett CL, Jepsen K, Jamieson CH, Carson D, Kipps TJ, Frazer KA.

PLoS Comput Biol. 2015 Mar 13;11(3):e1004105. doi: 10.1371/journal.pcbi.1004105. eCollection 2015 Mar.

20.

WITHDRAWN: The hydrophobic rich N- and C-terminal tails of beta-catenin facilitate nuclear import of beta-catenin.

Sharma M, Jamieson C, Lui C, Henderson BR.

J Biol Chem. 2014 Dec 3. pii: jbc.M114.603209. [Epub ahead of print]

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk